Clinical trialNCT01743131CompletedPhase 2Interventional

Abatacept as GVHD Prophylaxis Phase 2

SponsorBoston Children's HospitalEnrollment186Graft vs Host DiseaseMalignancy

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a phase II multi-center, randomized, double blind, placebo-controlled trial. The investigators are doing this study to see if a new drug, abatacept, can be used together with a calcineurin inhibitor (cyclosporine or tacrolimus) and methotrexate to provide better protection against Acute Graft versus Host Disease (aGvHD) without causing more infections.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Leslie Kean, MD, PhD
Boston Children's Hospital
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

14 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada

Children'S and Women'S Health Center of Bc
Vancouver, British Columbia, Canada

United States

Children'S Hospital Los Angeles
Los Angeles, California, United States
Ucsf Benioff Children'S Hospital Oakland
Oakland, California, United States
Children'S Hospital Colorado
Aurora, Colorado, United States
Children'S National Medical Center
Washington D.C., District of Columbia, United States
University of Florida
Gainesville, Florida, United States
Children'S Healthcare of Atlanta at Egleston
Atlanta, Georgia, United States
Emory University/winship Cancer Center
Atlanta, Georgia, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
University of Michigan
Ann Arbor, Michigan, United States
Washington University
St Louis, Missouri, United States
Michael Grimley
Cincinnati, Ohio, United States
University of Utah
Salt Lake City, Utah, United States
Seattle Cancer Care Alliance
Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Abatacept →Placebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 1 Feb 2013
Primary completion: 30 Jun 2018
Completion: 30 Mar 2024
Last update posted: 11 Dec 2025
Registered enrollment: 186
Registry id: NCT01743131

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.